Prasugrel
Patent Foramen Ovale
Columbia UniversitySmall moleculePhase 3Active
B
58/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 43/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the Patent Foramen Ovale cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Acetylsalicylic Acid Assistance Publique - Hôpitaux de Paris | Phase 4 | BBB |
Rivaroxaban Chinese Academy of Medical Sciences, Fuwai Hospital | Phase 3 | BB |
WARFARIN Columbia University | Phase 4 | BB |
Apixaban Mayo Clinic | Phase 3 | BB |
Dabigatran Assistance Publique - Hôpitaux de Paris | Phase 3 | BB |
Flecainide Assistance Publique - Hôpitaux de Paris | Phase 3 | B |
METOPROLOL Chinese Academy of Medical Sciences, Fuwai Hospital | Phase 2 | B |
Plavix Chinese Academy of Medical Sciences, Fuwai Hospital | Phase 3 | NR |
Same molecule, other indications
Prasugrel is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →